Palmitoylethanolamide

Spezifikationen

544-31-0CAS-Nummer

208-867-9EG-Nummer

N-(2-hydroxyethyl)hexadecanamideIUPAC-Name

C18H37NO2Chemische Formel

299.5 g/molMolekulargewicht

Palmitoylethanolamide; Palmidrol; 544-31-0; N-(2-Hydroxyethyl)hexadecanamide; Palmitoyl ethanolamide; Palmitic acid monoethanolamide; Hydroxyethylpalmitamide; Loramine P 256; palmitylethanolamide; Palmidrolum; Levagen; Palmdrol prodes; Monoethanolamine palmitic acid amide; palmitic monoethanolamide; Palmitinsaeure-beta-hydroxyethylamid; Anandamide (16:0); hexadecanoyl ethanolamide; N(2-hydroxyethyl)palmitide; 6R8T1UDM3V; N(2-hydroxyethyl) palmitide; NSC-23320; N-(2-hydroxyethyl)-palmitide; FSD-201; n-palmitoyl ethanolamide; AM 3112; CHEBI:71464; NSC23320; SCI-110 component palmitoylethanolamide; n-palmitoylethanolamide; N-(2-hydroxyethyl)palmitate; OptiPEA; RefChem:858399; 208-867-9; N-(2-Hydroxyethyl)palmitamide; Palmitamide MEA; Impulsin; N-palmitoylethanolamine; Palmitoyl-EA; HEXADECANAMIDE, N-(2-HYDROXYETHYL)-; Palmidrol [INN]; C18H37NO2; MFCD00020562; N-hexadecanoylethanolamine; NSC 23320; PEA (Chemical); DTXSID4042254; N-hexadecanoyl-ethanolamine; Palmidrol (INN); NAE 16:0; Palmitoylethanolamid?e; NCGC00015793-03; AM 3112;Loramine P 256;Mackpeart DR 14V; DTXCID2022254; Palmidrolum [INN-Latin]; CAS-544-31-0; 2-Palmitoylaminoethanol; SR-01000076055; EINECS 208-867-9; UNII-6R8T1UDM3V; MimyX; Palmitoyl ethanolamide; palmitoylethanolamide; Anandamide (16:0); N-palmitoyl ethanolamine; Anandamide C16:0; Tocris-0879; Oleic Acid Impurity 2; N-hexadecyl-ethanolamine; N-palmitoyl ethanolamine; PALMIDROL [MI]; Lopac-P-0359; PALMIDROL [MART.]; Palmityoletanolamide (PEA); 2-PALMITAMIDOETHANOL; PALMIDROL [WHO-DD]; CBiol_002043; Lopac0_000905; BSPBio_001454; KBioGR_000174; KBioSS_000174; MLS002153421; SCHEMBL120518; BML2-B10; CHEMBL417675; GTPL3622; orb1300340; Palmidrol|N-palmitoylethanolamine; BDBM29083; KBio2_000174; KBio2_002742; KBio2_005310; KBio3_000347; KBio3_000348; Bio1_000329; Bio1_000818; Bio1_001307; Bio2_000174; Bio2_000654; HMS1361I16; HMS1791I16; HMS1989I16; HMS2234L19; HMS3264C10; HMS3266N08; HMS3374K03; HMS3402I16; HMS3411B14; HMS3649L03; HMS3675B14; N-(2-hydroxyethyl) hexadecanamide; Pharmakon1600-01506156; CS-D1253; Tox21_110222; ANA(16:0); EBC-47502; LMFA08040013; NAE(16:0); NSC760371; s4708; AKOS002676363; Tox21_110222_1; CCG-204987; DB14043; FP76687; LP00905; NSC-760371; SDCCGSBI-0050880.P002; IDI1_033924; s10398; NCGC00015793-01; NCGC00015793-02; NCGC00015793-04; NCGC00015793-05; NCGC00015793-06; NCGC00015793-07; NCGC00015793-08; NCGC00015793-09; NCGC00015793-10; NCGC00015793-12; NCGC00024840-01; NCGC00024840-02; NCGC00024840-05; NCGC00024840-06; NCGC00024840-07; NCGC00024840-08; NCGC00024840-09; AS-14094; HY-20685; PALMITOYLETHANOLAMIDE [NFLIS-DRUG]; SMR000058371; SY211643; Hexadecanoic acid (2-hydroxy-ethyl)-amide; EU-0100905; NS00013930; P2670; T6926; D08328; EN300-311967; P 0359; AB00918319_06; F530116; Q2159860; SR-01000076055-1; SR-01000076055-3; SR-01000076055-7; BRD-K68095457-001-04-4; BRD-K68095457-001-10-1; BRD-K68095457-001-11-9; Z2242151306Synonyme